new Bioshares report 10/7/15

Thanks Doug , just had a read and was astounded by the positive comments from a Dr Cunningham who is a partner in the giant U.S. $1.7 billion fund Clarus Ventures.
He mentioned the potential for 50 fold upside upon clinical success and how he believes the risk reward profile for this stock is very favourable.
With a market cap of only $30 mill and almost $20 mill of that cap in cash and listed investments it seems very much under the radar in the bio space. Its share register has some major U.S bio funds on board plus Clarus watching closely in the background.
Also just had a look at the recent company asx presentation and compared to other companies in the same space it is amazing how far behind in listed value it is.
Looks very interesting